LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Wan, Yanzhi"
  2. AU="Jahan, Nuzrath"
  3. AU="Iannazzo, Roberta"
  4. AU="Lynn Henry, N"
  5. AU="Francesco Bonella"
  6. AU="Raviv, Yael" AU="Raviv, Yael"
  7. AU="Li, Chuhui"
  8. AU="Säämänen, Jari"
  9. AU="Attila Frigy"
  10. AU="Solyst, W"
  11. AU="Mitchell, Colleen C"
  12. AU="Kurbatov, Ilya Y"
  13. AU="Guevara-Álvarez, A"
  14. AU="Barker, Darren"
  15. AU="Muschaweckh, Andreas"
  16. AU="Saibi, Lotfi"
  17. AU=Wagener Jeffrey S AU=Wagener Jeffrey S
  18. AU="Christian Tschuschke"
  19. AU="Gong, Hexiang"
  20. AU="Ziembiec, Nancy A"
  21. AU="Hameed, Safraj Shahul"
  22. AU="Elliott, Alison M"
  23. AU="Nakeshbandi, Mohamed"
  24. AU=Sonthalia Nikhil AU=Sonthalia Nikhil
  25. AU="Kohanbash, Gary" AU="Kohanbash, Gary"
  26. AU=Nawrocki Mariusz J.
  27. AU="Jayme Borensztajn"
  28. AU=Schaerf Raymond H M
  29. AU="Chachar, Aijaz Zeeshan Khan"
  30. AU=Forster H V
  31. AU=Yang G-F
  32. AU="Kaplan, Robert C"
  33. AU="Rood, Julian I."
  34. AU="Manhes, Caroline"
  35. AU="Jacobsen, Cristiane Cavalcanti"
  36. AU="Anja Kukic"
  37. AU="Zhang, N"
  38. AU="Cunningham, Thomas J"
  39. AU="Wu, Y P"
  40. AU="Sumbul, Sabiha"
  41. AU="Razolli, Daniela S"
  42. AU="Asif, Mohsin"
  43. AU="Choudhary, Diksha"
  44. AU="Liu, Yongmei"
  45. AU=Goldshaid Liat
  46. AU="Sandeep Dhayade"
  47. AU="Ashkin, David"
  48. AU="Yukioka, Hideo"
  49. AU="Giles, M"
  50. AU="Keshavarzian, Tina"
  51. AU="Richard Holtmeier"
  52. AU=Sanborn Keri B
  53. AU=Crestani Larissa AU=Crestani Larissa
  54. AU=Nassiri Amir Ahmad
  55. AU="Keiser, Olivia"
  56. AU="Scholz, Martin"
  57. AU="Vassilis Pigadas" AU="Vassilis Pigadas"
  58. AU="Schlievert, Patrick M"
  59. AU=Egan Katie G
  60. AU="Benzadón, Mariano"
  61. AU="Truong, Thérèse"
  62. AU="de Oliveira, Aline Lima"
  63. AU="Lehto, Sonya G"
  64. AU="Simi Jacob"
  65. AU="Shipman, Michael"
  66. AU=Pons Linda
  67. AU="Notoya, A"
  68. AU="Williams, Olajide A"
  69. AU=Errington Jeff
  70. AU="Tortolani, Christina C"
  71. AU="Patel, Jenil R"
  72. AU="Aires, Rafaela"
  73. AU="Habibelahi, Abbas"
  74. AU="Temes, Javier"
  75. AU="Miwa, Toru"
  76. AU="Jaller, Elvira"
  77. AU="Manso Sanchez, L M"

Suchergebnis

Treffer 1 - 2 von insgesamt 2

Suchoptionen

  1. Artikel: Regorafenib combined with sintilimab as second-line treatment for advanced HCC patient: a case report.

    Wan, Yanzhi / Zhu, Hong

    Frontiers in oncology

    2023  Band 13, Seite(n) 1256137

    Abstract: Hepatocellular carcinoma (HCC) is a tumor with a high degree of malignancy. Patients have poor outcomes and short survival times, especially after progression to first-line systemic therapy. Regorafenib is the standard second-line treatment for HCC, but ... ...

    Abstract Hepatocellular carcinoma (HCC) is a tumor with a high degree of malignancy. Patients have poor outcomes and short survival times, especially after progression to first-line systemic therapy. Regorafenib is the standard second-line treatment for HCC, but there is no conclusive evidence that regorafenib combined with immunotherapy can be used as a second-line treatment. We present the case of a 50-year-old man with a chronic hepatitis B (CHB) infection for more than 30 years who was diagnosed with stage Barcelona Clinic Liver Cancer (BCLC)-B hepatocellular carcinoma. Unfortunately, recurrence and metastasis occurred soon after radical surgery and standard first-line treatment with lenvatinib. The patient was then treated with regorafenib plus sintilimab as second-line treatment. Surprisingly, soon after treatment, the patient reached a state of partial response (PR) that lasted for more than one year, which is currently close to that of complete response (CR). Regorafenib combined with sintilimab as second-line treatment showed an excellent curative effect in this patient, who had HCC with multiple metastases to the liver and lungs. This treatment, which has tolerable side effects, enabled the patient to reach a state of PR that lasted over one year, which is currently close to CR. Therefore, it may be a potential second-line treatment strategy.
    Sprache Englisch
    Erscheinungsdatum 2023-10-10
    Erscheinungsland Switzerland
    Dokumenttyp Case Reports
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2023.1256137
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: A gene signature predicting prognosis of patients with lower-grade gliomas receiving temozolomide therapy.

    Wan, Yanzhi / Li, Guangqi / Deng, Junyue / Zhu, Hong / Ma, Xuelei

    Discover. Oncology

    2023  Band 14, Heft 1, Seite(n) 202

    Abstract: Temozolomide (TMZ) has been used as a first-line therapy against lower-grade gliomas (LGGs) combined with other chemotherapy drugs. However, there has been no reliable index predicting TMZ response of patients with LGGs. In this study, we aim to ... ...

    Abstract Temozolomide (TMZ) has been used as a first-line therapy against lower-grade gliomas (LGGs) combined with other chemotherapy drugs. However, there has been no reliable index predicting TMZ response of patients with LGGs. In this study, we aim to investigate the relationship between gene expressions and the prognosis of TMZ therapy in LGGs. We integrated transcriptome and clinical data of 171 LGGs from the Chinese Glioma Genome Atlas (CGGA). Consensus LASSO Cox regression was used to identify 14 key genes related to different clinical outcomes under TMZ chemotherapy. We constructed and evaluated a risk score based on the 14 genes. Patients with LGGs of lower risk scores (low-risk group) generally had better survival than those LGGs of higher risk scores (high-risk group), which is independent of clinicopathological factors. High-risk patients showed activation of innate and humoral-type immunity. The prognostic contribution of the risk score was validated in an independent validation cohort of 65 patients. Besides, combined with three independent predictors (grade, IDH1 mutation status, and chr1p19q co-deletion status), we further developed a nomogram to predict the benefit of TMZ treatment in LGGs. Our results indicate that a transcriptome-based index can optimize the treatment strategy for patients with LGGs under TMZ therapy.
    Sprache Englisch
    Erscheinungsdatum 2023-11-13
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ISSN 2730-6011
    ISSN (online) 2730-6011
    DOI 10.1007/s12672-023-00818-9
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

Zum Seitenanfang